OverviewSuggest Edit

Tiziana Life Sciences plc is a UK biotechnology company that focuses on the discovery and development of novel molecules that treat human disease in oncology and immunology. The Company is focused on its lead compound, milciclib, a molecule which blocks the action of specific enzymes called cyclin-dependent kinases (CDK) involved in cell division as well as a number of other protein kinases. Milciclib is currently in phase II clinical trials for thymic carcinoma in patients previously treated with chemotherapy. The Company is also in clinical development of foralumab. Foralumab is the only fully human engineered anti-human CD3 antibody in clinical development. This phase II compound has potential application in a wide range of autoimmune and inflammatory diseases, such as ulcerative colitis, multiple sclerosis, type-1 diabetes (T1D), inflammatory bowel disease (IBD), psoriasis and rheumatoid arthritis, where modulation of a T-cell response is desirable. Tiziana Life Sciences’ research team has discovered that Bcl-3 has a prominent role in the metastasis of mammary cancers, and has elucidated the mechanism of Bcl-3 action to be a regulator of cancer cell motility. Tiziana has also determined that Bcl-3 inhibition suppresses cell motility in triple-negative, HER-2-positive PR- and ER-positive breast cancer sub-types, suggesting that Bcl-3 may be a master regulator of this metastatic property not only in aggressive breast cancers, but across the clinical spectrum of breast disease. The Company anticipates that Bcl-3 will progress to clinical trials in 2016. ... Show more
TypePublic
Founded2013
HQLondon, GB
Websitetizianalifesciences.com

Latest Updates

Employees (est.) (Jun 2017)6(+20%)
Revenue (FY, 2015)(£6.3 M)(+692%)
Share Price (Nov 2018)$10.6

Key People/Management at Tiziana Life Sciences

Gabriele Cerrone

Gabriele Cerrone

Executive Chairman
Ricardo Dalla-Favera

Ricardo Dalla-Favera

Non-Executive Director
Willy Simon

Willy Simon

Non-Executive Director
Leopoldo Zambeletti

Leopoldo Zambeletti

Non-Executive Director
Tiziano Lazzaretti

Tiziano Lazzaretti

CFO
Show more

Tiziana Life Sciences Office Locations

Tiziana Life Sciences has an office in London
London, GB (HQ)
18 South St
Show all (1)
Report incorrect company information

Tiziana Life Sciences Financials and Metrics

Tiziana Life Sciences Revenue

Tiziana Life Sciences's revenue was reported to be (£6.29 m) in FY, 2015 which is a 691.8% increase from the previous period.
GBP

Net income (FY, 2017)

(6.8m)

EBITDA (FY, 2017)

(8.2m)

EBIT (FY, 2017)

(8.2m)

Closing stock price (21-Nov-2018)

10.6

Cash (31-Dec-2017)

48.0k
GBPFY, 1999FY, 2000FY, 2001FY, 2002FY, 2003FY, 2004FY, 2005FY, 2006FY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

99.0k116.0k405.0k311.0k91.7k56.1k187.7k(82.0k)(195.0k)(794.0k)(6.3m)

Revenue growth, %

692%

Cost of goods sold

45.0k40.0k209.0k108.0k20.4k11.0k69.9k

Gross profit

54.0k76.0k196.0k203.0k71.3k45.0k117.9k
GBPFY, 1999FY, 2000FY, 2001FY, 2002FY, 2003FY, 2004FY, 2005FY, 2006FY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

157.5k2.2m1.1m6.6k996.0k771.0k942.0k508.0k588.0k25.2k30.4k69.4k33.0k4.0k2.3m8.9m4.7m48.0k

Accounts Receivable

54.0k35.0k60.0k56.0k16.0k23.8k38.4k

Inventories

1.0k4.0k20.0k7.0k28.6k38.2k10.5k

Current Assets

236.4k2.6m1.4m677.4k1.5m1.9m1.3m873.0k954.0k221.4k165.2k182.7k462.0k27.0k2.5m9.3m5.0m1.8m
GBPFY, 1999FY, 2000FY, 2001FY, 2002FY, 2003FY, 2004FY, 2005FY, 2006FY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(553.9k)(987.3k)(2.3m)(2.3m)(2.0m)(1.4m)(2.1m)(2.3m)(2.4m)(1.4m)(729.9k)(1.1m)(778.0k)(653.0k)(3.3m)(8.6m)(7.2m)(6.8m)

Cash From Operating Activities

534.7k1.1m2.5m1.8m1.6m1.8m1.3m2.2m2.2m(914.4k)(547.5k)(403.8k)(853.0k)(210.0k)(2.2m)(5.5m)(5.1m)(5.9m)

Cash From Financing Activities

392.7k4.7m1.3m488.5k2.0m1.7m1.4m1.7m2.3m451.2k598.7k554.7k1.5m67.0k4.4m12.1m1.2m1.2m

Net Change in Cash

405.3k170.1k178.8k211.3k117.0k120.0k18.0k8.0k102.0k(563.9k)8.3k48.6k33.0k(29.0k)2.3m6.6m(4.2m)(4.7m)
GBPY, 2017

Financial Leverage

-1.1 x
Show all financial metrics
Report incorrect company information

Tiziana Life Sciences Online and Social Media Presence

Embed Graph
Report incorrect company information

Tiziana Life Sciences Blogs

Equity Placing to raise US$1,500,000

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014Tiziana Life Sciences plc("Tiziana" or the "Company")London, October 26, 2018 - Tiziana Life Sciences plc (AIM: TILS), a UK biotechnology company that focuses on the discovery and development of…

Tiziana Announces Filing of an Amended Registration Statement with the SEC

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTIONLondon…

Tiziana Life Sciences Announces that it will be presenting data from animal studies demonstrating the potential synergistic activity of Milciclib with Tyrosine Kinase Inhibitors to treat Hepatocellular Carcinoma (HCC) at the American Association for the Study of Liver Diseases (AASLD) Meeting (9th to 13th November 2018 in San Francisco)

London, 16 October 2018- Tiziana Life Sciences plc (AIM: TILS), a clinical stage biotechnology company developing targeted drugs for cancer and inflammatory diseases, will present results from preclinical studies demonstrating synergistic activity of milciclib with sorafenib (NexavarR) to suppress t…

Tiziana Announces Launch of Offering and Application to List on the Nasdaq Capital Market

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTIONLondon…

Interim Results for the Six Months Ended 30 June 2018 Advancing pipeline of next generation therapeutics and diagnostics for oncology and immune diseases of high unmet need

London, 24 September 2018 – Tiziana Life Sciences plc (“Tiziana”, AIM: TILS), the research and clinical stage biotechnology company focussing on proprietary drug candidates to treat cancer and autoimmune diseases, today announces its interim results for the six months ended 30 June 2018.Highlights d…

U.S. Food and Drug Administration approves application for Investigational New Drug; Phase I Clinical Study set to commence enrolment in late 2018

THE INFORMATION CONTAINED IN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE EU MARKET ABUSE REGULATION (596/2014). UPON PUBLICATION OF THE ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN…
Show more

Tiziana Life Sciences Company Life and Culture

Report incorrect company information

Tiziana Life Sciences Frequently Asked Questions

  • When was Tiziana Life Sciences founded?

    Tiziana Life Sciences was founded in 2013.

  • Who are Tiziana Life Sciences key executives?

    Tiziana Life Sciences's key executives are Gabriele Cerrone, Ricardo Dalla-Favera and Willy Simon.

  • How many employees does Tiziana Life Sciences have?

    Tiziana Life Sciences has 6 employees.

  • Who are Tiziana Life Sciences competitors?

    Competitors of Tiziana Life Sciences include ContraFect, MedNet Solutions and Bio-Rad.

  • Where is Tiziana Life Sciences headquarters?

    Tiziana Life Sciences headquarters is located at 18 South St, London.

  • Where are Tiziana Life Sciences offices?

    Tiziana Life Sciences has an office in London.

  • How many offices does Tiziana Life Sciences have?

    Tiziana Life Sciences has 1 office.